Reprint

Therapeutic Landscapes in Colorectal Carcinoma

Edited by
November 2023
142 pages
  • ISBN978-3-0365-9441-5 (Hardback)
  • ISBN978-3-0365-9440-8 (PDF)

This book is a reprint of the Special Issue Therapeutic Landscapes in Colorectal Carcinoma that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary

The Special Issue, titled “Therapeutic Landscapes in Colorectal Carcinoma”, illustrates a stimulating collection of articles written by international specialists that can promote discussions and ideas among colleagues working on CRC. It provides us with a deeper insight into the latest advances involving knowledge on CRC from scientific, translational, and clinical points of view. Through this Special Issue, our main purpose was to shed light on some state-of-the-art research on CRC. Here, the reader will find papers on prognostic factors as well as responses to neoadjuvant and adjuvant CRC treatments. Finally, we discuss the research trends and hotspots for CRC therapies that emerged during the COVID-19 pandemic, such as the potential achievement of a transition from CRC clinical research to precision medicine, together with a special emphasis given to new single-cell-based techniques. We hope that it can encourage translational and interdisciplinary collaborations, leading to a definitive understanding of strategies to overcome and inhibit CRC progression and metastasis.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
colorectal cancer; inflammatory pathways; NFKB; RIPK2; MSI; dMMR; colorectal; cancer; immunotherapy; Romania; incidence; PCR; IHC; drug development; targeted therapies; preclinical candidates; databases; cancer therapeutics; colorectal cancer; TGF-b; regorafenib; colorectal carcinoma; intratumor heterogeneity; single-cell next-generation sequencing; precision medicine; metastatic colorectal cancer; BRAF mutation; triple target therapy; colorectal cancer screening; COVID-19; SARS-CoV-2; colon cancer; cell line models; dependencies; targeted therapy; signal transduction; neoadjuvant chemotherapy (NAC); locally advanced colon cancer (LACC); preoperative treatment; propensity score matching; survival; liver transplantation; de novo malignancy; colorectal carcinoma; immunosuppression; uracil–tegafur; colon cancer; chemotherapy; adjuvant therapy; stage IIA; n/a